Scinai Immunotherapeutics (SCNI) Common Equity (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 11 years of Common Equity data on file, last reported at $11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity changed N/A year-over-year to $11.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.8 million (changed N/A YoY), and the FY2025 full-year result was $8.1 million, down 18.78% from the prior year.
• Common Equity climbed to $11.8 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.8 million in Q1 2026 to a low of -$7.3 million in Q2 2024.
• A 5-year average of $1.2 million and a median of -$862000.0 in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 656.93% in 2023 and jumped 471.58% in 2024, its largest moves.
• Tracing SCNI's Common Equity over 5 years: stood at -$1.8 million in 2022, then tumbled by 159.6% to -$4.6 million in 2023, then surged by 318.36% to $10.0 million in 2024, then declined by 18.78% to $8.1 million in 2025, then soared by 45.14% to $11.8 million in 2026.
• Business Quant data shows SCNI's Common Equity at $11.8 million in Q1 2026, $8.1 million in Q4 2025, and $7.9 million in Q2 2025.